Johnson Controls International PLC vs GeneDx Holdings Corp — how do they compare? Johnson Controls International PLC trades at $157.44 (market cap $93.28B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Johnson Controls International PLC is far larger — about 46.2× GeneDx Holdings Corp's market cap, and Johnson Controls International PLC pays a 1.04% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson Controls International PLC for 65 Days and GeneDx Holdings Corp for 19 Days on average.
| JCI | WGS | |
|---|---|---|
Market Cap | $93.28B | $2.02B |
Volume | 2,786,476 | 734,640 |
Sector | Basic Materials | Health |
52-Week High | $158.76 | $167.51 |
52-Week Low | $105.55 | $34.51 |
Typical Hold Time | 65 Days | 19 Days |
Enterprise Value | $102.12B | $2.05B |
Dividend Yield | 1.04% | — |
Signals from Pluang's Aura AI — not financial advice
Johnson Controls (JCI) trades at $154.00, down 1.24% on the day, with strong technical momentum showing bullish moving averages and neutral oscillators. The company demonstrates robust fundamentals with Q3 2026 EPS of $1.42 beating expectations by 9.2% and raising full-year guidance. Revenue trends show recovery from $23.0B in 2024 to $23.6B in 2025, with net income margin expanding significantly to 13.94%. Recent news highlights strong demand for data-center thermal management systems and inclusion in AI industrial stock recommendations.
JCI presents a compelling investment case with 62% analyst buy ratings and $172.50 consensus price target offering 12% upside. The company benefits from strong AI-driven demand in thermal management systems, though elevated P/E of 43.38 and debt-to-asset ratio increasing to 26.06% warrant monitoring. Execution on raised FY26 guidance and data-center market expansion remain key catalysts for continued growth.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →